Surveillance for Nosocomial Infections in Pediatric Cancer Patients

NCT00843804 | Unknown

• 1 other identifier: 03/07
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The Oncoped 2006 study implements a multicenter prospective surveillance module for nosocomial infections in pediatric cancer patients.

Conditions

Nosocomial Infections; Bloodstream Infection; Invasive Aspergillosis

Keywords

nosocomial infection; bloodstream infection; central venous catheter; invasive Aspergillosis; Clostridium difficile associated disease

Eligibility Criteria

• Age: Up to 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Pediatric patients with cancer during intensive induction / reinduction treatment (including conventional chemotherapy, radiotherapy and stem cell transplantation).

You may qualify if:

• pediatric cancer patients receiving inpatient treatment with chemotherapy, -
• radiotherapy or stem cell transplantation

You may not qualify if:

• no informed consent
• no inpatient treatment

Sponsors & Collaborators

• University Hospital, Bonn: lead

Study Sites (1)

Children's Hospital, Pediatric Oncology UNit

Bern, CH 3010, Switzerland

RECRUITING

Related Publications (5)

• Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH. Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol. 2000 Sep;21(9):592-6. doi: 10.1086/501809.

  PMID: 11001263 BACKGROUND

• Simon A, Bode U, Fleischhack G, Kramer M. Surveillance of nosocomial infections in pediatric cancer patients. Am J Infect Control. 2005 Dec;33(10):611. doi: 10.1016/j.ajic.2005.09.005. No abstract available.

  PMID: 16330311 BACKGROUND

• Simon A, Fleischhack G, Wiszniewsky G, Hasan C, Bode U, Kramer MH. Influence of prolonged use of intravenous administration sets in paediatric cancer patients on CVAD-related bloodstream infection rates and hospital resources. Infection. 2006 Oct;34(5):258-63. doi: 10.1007/s15010-006-5646-y.

  PMID: 17033749 BACKGROUND

• Simon A, Groger N, Wilkesmann A, Hasan C, Wiszniewsky G, Engelhart S, Kramer MH, Bode U, Ammann RA, Fleischhack G. Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. Int J Antimicrob Agents. 2006 Nov;28(5):417-22. doi: 10.1016/j.ijantimicag.2006.08.007. Epub 2006 Oct 12.

  PMID: 17046210 BACKGROUND

• Simon A, Besuden M, Vezmar S, Hasan C, Lampe D, Kreutzberg S, Glasmacher A, Bode U, Fleischhack G. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer. 2007 Feb;15(2):213-20. doi: 10.1007/s00520-006-0125-7. Epub 2006 Aug 30.

  PMID: 16944217 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Blood culture isolates

MeSH Terms

Conditions

Cross Infection; Sepsis

Condition Hierarchy (Ancestors)

Infections; Iatrogenic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Systemic Inflammatory Response Syndrome; Inflammation

Study Officials

• Arne Simon, MD

  Children's Hospital Medical Center, University of Bonn, Germany

  PRINCIPAL INVESTIGATOR

• Roland Ammann, MD

  Children's Hosptial, Bern, Switzerland

  STUDY DIRECTOR

• Hans-Jürgen Lawas, MD

  Children's Hospital Medical Center, Düsseldorf, Germany

  STUDY CHAIR

Central Study Contacts

Arne Simon, MD

CONTACT

004922828733254; asimon@ukb.uni-bonn.de

Udo Bode, MD

CONTACT

004922828733310; udo.bode@ukb.uni-bonn.de

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 12, 2009
• First Posted: February 13, 2009
• Study Start: March 1, 2007
• Study Completion: June 1, 2010
• Last Updated: June 28, 2010

Record last verified: 2009-02

Locations

CH (1)